ReviewCurrent neuropharmacology2026
Molecular Mechanisms of Dopaminergic Neuron Degeneration in Parkinson's Disease: A Comprehensive Review.
Review in Current neuropharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unraveling the Mechanistic Insights ofNutrients · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is a neurological condition that starts with the degeneration of neurons. Neurons play a crucial role in producing dopamine (DA), a type of neurotransmitter that primarily regulates bodily functions such as motor control, posture, motivation, reward, pleasure, cognition, and memory. Other variables that contribute to the disorder include the buildup of Lewy bodies and Lewy neurites, which are composed of increased α-synuclein (α-syn). Depletion of DA in the striatal area and the death of DA-producing neurons are often considered the basis for the motor impairments seen in PD. In addition, both genetic and environmental factors may play a role in PD etiology; specifically, genetic variations and exposure to toxins may contribute to the development of brain lesions. The article aims to outline the current state of knowledge on the dopaminergic pathway and how PD affects DA homeostasis. Various molecular mechanisms are involved in the pathogenesis of PD, including α-syn aggregation, lysosomal and chaperone-mediated autophagy, mitochondrial dysfunction, and abnormal regulation of calcium homeostasis. Intrinsic and extrinsic caspase-mediated apoptosis, autophagic cell death, and ferroptosis are also involved in neurodegeneration that often leads to PD. The occurrence of PD can be controlled by the inclusion of antioxidants, such as mitoquinone, which inhibit mitochondrial oxidative damage, as well as modulation of autophagy, proteostasis, gene therapy, and its editing, and stem cell regeneration. Diverse mechanistic pathogenesis and genetic variations make PD a complicated disease to tackle. Potential treatment approaches, such as modulating autophagy-lysosomal pathways and protecting mitochondria, may be better understood with deeper insight into these mechanisms. We conclude by highlighting current and upcoming gene and cell therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.